KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax (2022 - 2025)

Acadia Pharmaceuticals (ACAD) has 2 years of Long-Term Deferred Tax data on record, last reported at $6.8 million in Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax rose 466.67% year-over-year to $6.8 million; the TTM value through Dec 2023 reached $6.8 million, up 466.67%, while the annual FY2023 figure was $6.8 million, 466.67% up from the prior year.
  • Long-Term Deferred Tax reached $6.8 million in Q4 2023 per ACAD's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $6.8 million in Q4 2023 and bottomed at $1.2 million in Q4 2022.